Building Tomorrow’s
Medicines Today
Autonomous Design of Small Molecule Therapeutics using Generative AI
Autonomous AI Drug Design
Create and screen novel small molecules—faster, cheaper, and with fewer failures—through our intuitive deep-learning platform.
Collaborating with researchers from: Scripps Calibr, Johns Hopkins, Temple University, Mayo Clinic, UC Irvine, University of Florida, University of Kentucky, Aragen, and the Gates Foundation
Our Expertise
Our team has a distinguished track record of advancing drug candidates from discovery through development, collectively contributing to 35 approved therapies. We have authored numerous peer-reviewed publications, secured foundational patents, and supported substantial capital raises across the biotech sector.
Our expertise spans oncology, central nervous system (CNS) disorders, metabolic diseases, and infectious diseases. Our members have held leadership positions at top pharmaceutical companies and research institutions, built and led successful innovation centers, and advised on AI-driven strategies that are reshaping the future of drug discovery.
By combining deep scientific insight with real-world execution experience, we are uniquely positioned to lead in the rapidly evolving landscape of therapeutic innovation.
